Juan Andres - 20 Aug 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
20 Aug 2021
Transactions value $
-$3,702,850
Form type
4
Filing time
24 Aug 2021, 16:29:05 UTC
Previous filing
20 Aug 2021
Next filing
27 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K 20 Aug 2021 Direct F1
transaction MRNA Common Stock Sale -$1.87M -5K -100% $374.88 0 20 Aug 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K 23 Aug 2021 Direct F1
transaction MRNA Common Stock Sale -$1.95M -5K -100% $390.11 0 23 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -1.47% $0.00 335K 20 Aug 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -1.49% $0.00 330K 23 Aug 2021 Common Stock 5K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer